Vuity™

Drug - Vuity™ (pilocarpine 1.25% ophthalmic solution) [Abbvie Inc.]

April 2022

Therapeutic area - Ophthalmics Agents

Initial approval criteria

Patient has a diagnosis of presbyopia AND
Patient is 40 to 55 years of age AND
Vuity is prescribed by or in consultation with an optometrist or ophthalmologist AND
Patient has a documented contraindication and/or failure of corrective lenses (eyeglasses or contacts) to resolve presbyopia symptoms AND
Patient does not have a hypersensitivity to pilocarpine or any other component of the product AND
Patient does not have glaucoma or ocular hypertension AND
Patient will NOT receive concomitant treatment with any other ophthalmic pilocarpine formulation AND
Patient has been counseled to seek immediate medical care if they experience sudden onset of vision loss AND
Patient does not have iritis AND
For contact wearers, the patient has been advised to remove contact lenses prior to instillation of Vuity drops and to wait 10 minutes after dosing to reinsert contact lenses.
Initial approval is for 6 months

Patient continues to meet the above criteria AND
Patient experienced disease response as indicated by improvement in presbyopia AND
Patient is free of unacceptable toxicity from the drug (e.g., retinal detachment event, iritis, hypersensitivity to Vuity)
Renewal is for 12 months

MHCP Provider Resource Center 651-431-2700 or 1-800-366-5411